A randomized, double-blind study to evaluate the safety, tolerability, and pharmacokinetics of a supratherapeutic dose of GSK1349572 250 mg and a randomized, open-label study to evaluate the effects of omeprazole 40 mg daily and a high fat meal on the pharmacokinetics of GSK1349572 50 mg in healthy adult subjects (ING112941).

Trial Profile

A randomized, double-blind study to evaluate the safety, tolerability, and pharmacokinetics of a supratherapeutic dose of GSK1349572 250 mg and a randomized, open-label study to evaluate the effects of omeprazole 40 mg daily and a high fat meal on the pharmacokinetics of GSK1349572 50 mg in healthy adult subjects (ING112941).

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2009

At a glance

  • Drugs Dolutegravir; Dolutegravir; Omeprazole
  • Indications Dyspepsia; Gastritis; Gastro-oesophageal reflux; HIV-1 infections; Peptic ulcer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Aug 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top